Sélectionner la langue
DPPIV
DPPIV Informations sur la molécule
| Nom anglais | Dipeptidyl peptidase IV | Nombre de médicaments commercialisés | 42 |
| Nombre de médicaments cliniques | 37 | Alias de la cible | Dipeptidyl peptidase IV membrane form，T-cell activation antigen CD26，Adenosine deaminase complexing protein 2，Dipeptidyl peptidase IV，Dipeptidyl peptidase IV soluble form，ADCP2，Dipeptidyl peptidase 4，ADCP-2，ADABP，DPP4，Dipeptidylpeptidase IV (CD26， Adenosine Deaminase Complexing Protein 2)，DPP IV，TP103，CD26，Dipeptidyl-Peptidase 4，Dipeptidylpeptidase 4，CD26 Antigen，DPPIV，Xaa-Pro-Dipeptidylaminopeptidase，Gly-Pro Naphthylamidase，Post-Proline Dipeptidyl Aminopeptidase IV |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Dipeptidyl peptidase IV |
| Alias de la cible | Dipeptidyl peptidase IV membrane form，T-cell activation antigen CD26，Adenosine deaminase complexing protein 2，Dipeptidyl peptidase IV，Dipeptidyl peptidase IV soluble form，ADCP2，Dipeptidyl peptidase 4，ADCP-2，ADABP，DPP4，Dipeptidylpeptidase IV (CD26， Adenosine Deaminase Complexing Protein 2)，DPP IV，TP103，CD26，Dipeptidyl-Peptidase 4，Dipeptidylpeptidase 4，CD26 Antigen，DPPIV，Xaa-Pro-Dipeptidylaminopeptidase，Gly-Pro Naphthylamidase，Post-Proline Dipeptidyl Aminopeptidase IV |
| Nombre de médicaments commercialisés | 42 |
| Nombre de médicaments cliniques | 37 |
| Phase de R&D la plus avancée | Approved |
DPPIV Liste de produits
- Attribut
Protein (8)
- Bibliothèque de produits
En ligne (8)
- Espèces
Human (5)Mouse (1)Cynomolgus (1)Canine (1)
- Étiquette
His Tag (4)Fc Tag (1)Tag Free (1)His Tag & Avi Tag (2)
- Marqueur
Unconjugated (6)Biotin-labeled (2)
Ajouter au panier
Quantité totale8
- 1
DPPIVContexte de la molécule
Dipeptidyl peptidase-IV (DPPIV) is also known as adenosine deaminase complexing protein 2, DPPIV or CD26 is antigenic enzyme expressed on the surface of most cell types and is associated with immune regulation, signal transduction and apoptosis. It is an intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides. The substrates of DPPIV are proline (or alanine)-containing peptides and include growth factors, chemokines, neuropeptides, and vasoactive peptides. DPPIV plays a major role in glucose metabolism. It is responsible for the degradation of incretins such as GLP-1. DPPIV plays an important role in tumor biology, and is useful as a marker for various cancers, with its levels either on the cell surface or in the serum increased in some neoplasms and decreased in others. DPPIV also binds the enzyme adenosine deaminase specifically and with high affinity. The significance of this interaction has yet to be established.
DPPIVAlias de la molécule
DPP4,ADABP,ADCP2,CD26,DPPIV,TP103
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Dutogliptin Tartrate | REC-01; PHX-1149; PHX-1149T | Phase 3 Clinical | Phenomix | Diabetes Mellitus, Type 2; Leukemia, Myeloid, Acute; Myocardial Infarction; Renal Insufficiency; ST Elevation Myocardial Infarction | Details |
| Yogliptin | Phase 3 Clinical | Chengdu Easton Biopharmaceuticals Co Ltd, Sichuan Sunheal Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Empagliflozin/Sitagliptin Hydrochloride | DW1026C1; DW-1026C1; DW1026C2; DW-1026C2 | Phase 3 Clinical | Daewon Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Dapagliflozin formate/Linagliptin | IN-C009; AJU-A51 | Phase 3 Clinical | Aju Pharm Co Ltd, HK inno.N Corporation | Diabetes Mellitus, Type 2 | Details |
| DA5221-B2 | DA5221-B2 | Phase 3 Clinical | Dong-A ST Co Ltd | Diabetes Mellitus, Type 2 | Details |
| LID104 | LID104; LID-104 | Phase 3 Clinical | Ems | Diabetes Mellitus, Type 2 | Details |
| Empagliflozin/Metformin/Sitagliptin (Chong Kun Dang Pharmaceutical) | CKD-379 | Phase 3 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| TOTUM•63 | TOTUM-63 | Phase 3 Clinical | Valbiotis | Diabetes Mellitus, Type 2 | Details |
| Talabostat | VbP; PT-100; BXCL-701 | Phase 2 Clinical | Point Therapeutics | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Small Cell; CNS Embryonal Tumor; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Solid tumours | Details |
| TQ-F3083 | TQ-F3083; CT-383 | Phase 2 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Begelomab | SAND-26; BT 5/9 | Phase 2 Clinical | Adienne | Dermatomyositis; Graft vs Host Disease | Details |
| Singletine | DC-291407; DC-407; DC291407 | Phase 2 Clinical | Cisen Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Diabetes Mellitus, Type 2; Fatty Liver | Details |
| GCP-002 | EP-HMRG | Phase 2 Clinical | Goryo Chemical Inc | Esophageal Neoplasms | Details |
| Metformin/Dapagliflozin/Sitagliptin | GMRx4 | Phase 2 Clinical | George Medicines PTY Ltd, George Medicines UK Ltd | Diabetes Mellitus, Type 2 | Details |
| Bogliptin maleate | HL012MA | Phase 2 Clinical | East China University Of Science And Technology, Shandong Baiji Dichang Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Diabetes Mellitus, Type 2 | Details |
| CKD-393 | CKD-393 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
| Augliptin Hydrochloride | Phase 1 Clinical | Nanjing Changao Pharmaceutical Science And Technologyco Ltd, Shanghai Sun-Sail Pharmaceutical Science & Technology Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Evogliptin Tartrate | LY-05007 | Phase 1 Clinical | Dong-A Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Telmisartan | HDDO-16091 + HDDO-16092; HOB-077; HDDO-1609 | Phase 1 Clinical | Hyundai Pharmaceutical Co Ltd | Diabetes Mellitus; Hypertension | Details |
| TSL-0319 | TSL-0319 | Phase 1 Clinical | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Prusogliptin/Dapagliflozin/Metformin | Phase 1 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Vildagliptin and Metformin Hydrochloride Extended-Release Tablets(24h)(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Vildagliptin and Metformin Hydrochloride Extended-Release Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Alogliptin and Metformin Hydrochloride Sustained-release Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| CTL-02 | CTL-02; CTL02 | Phase 1 Clinical | Celltrion Inc | Details | |
| Vildagliptin Sustained-release Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| AJU-A53 | AJU-A53 | Phase 1 Clinical | Aju Pharm Co Ltd | Diabetes Mellitus, Type 2 | Details |
| CKD-393(2) | CKD-393(2) | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
| ZHB-015 | ZHB-015; ZHB015; ZHB-C003 | Phase 1 Clinical | Zonhon Biopharma Institute Inc | Solid tumours | Details |
| CMR-316 | CMR316; CMR-316 | Phase 1 Clinical | The Calibr-Skaggs Institute for Innovative Medicines | Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive; Respiratory Distress Syndrome, Adult | Details |
| Vildagliptin/Empagliflozin/Metformin Hydrochloride | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| CGT-2201 | CGT-2201 | Phase 1 Clinical | Cgenetech(Suzhou China) Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Empagliflozin/Metformin/Sitagliptin (Overseas Pharmaceuticals) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| THDBH-100 | THDBH100; THDBH101 | Phase 1 Clinical | Wuxi Apptec(Shanghai) Co Ltd | Diabetes Mellitus, Type 2 | Details |
| WXSHC-071 | WXSHC-071 | Phase 1 Clinical | Dongbao Zixing (Hangzhou) Biological Medicine Co Ltd | Diabetes Mellitus, Type 2 | Details |
| REC-04 | Clinical | Recardio Inc | Cardiovascular Diseases | Details | |
| DASH inhibitor (Bach) | Clinical | Bach Biosciences LLC | Neoplasms | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemigliptin L-tartrate Sesquihydrate | LC-150444; LC-15-0444 | Approved | Lg Chemical Ltd | Gemiglo, Zemiglo | South Korea | Diabetes Mellitus, Type 2 | Lg Chemical Ltd | 2012-06-27 | Diabetes Mellitus, Type 2; Fasting; Hepatic Insufficiency | Details |
| Gemigliptin L-tartrate Sesquihydrate/Metformin Hydrochloride | Approved | Lg Chemical Ltd | ZemiMet SR | South Korea | Diabetes Mellitus, Type 2 | Lg Chemical Ltd | 2015-01-01 | Diabetes Mellitus, Type 2 | Details | |
| Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride | Approved | Handok Inc | Tenelia M SR | South Korea | Diabetes Mellitus, Type 2 | Handok Inc | 2015-11-03 | Diabetes Mellitus, Type 2 | Details | |
| Evogliptin | DA-1229; RNV-1001 | Approved | Dong-A Pharmaceutical Co Ltd | Sugarnon, Evodine, Suganon, SUGANON | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-10-02 | Aortic valve diseases; Diabetes Mellitus, Type 2; Liver Dysfunction; Renal Insufficiency | Details |
| Saxagliptin Hydrate | BMS-477118; BMS-477118-11; OPC-262 | Approved | Bristol-Myers Squibb Company | 安立泽, Onglyza | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2009-07-31 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia | Details |
| Teneligliptin Hydrobromide Hydrate | MP-513 | Approved | Mitsubishi Tanabe Pharma | Tenglyn, Tenelia | Japan | Diabetes Mellitus, Type 2 | Mitsubishi Tanabe Pharma, Daiichi Sankyo Co Ltd | 2012-06-29 | Diabetes Mellitus, Type 2 | Details |
| Retagliptin Phosphate | SP-2086 Phosphate; SP 2086 | Approved | Jiangsu Hengrui Medicine Co Ltd | 瑞泽唐 | Mainland China | Diabetes Mellitus, Type 2 | Jiangsu Hengrui Medicine Co Ltd | 2023-06-27 | Diabetes Mellitus; Diabetes Mellitus, Type 2; Renal Insufficiency | Details |
| Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline | MK-0431J | Approved | Astellas Pharma Inc, Merck & Co Inc | Sujanu | Japan | Diabetes Mellitus, Type 2 | null | 2018-03-23 | Diabetes Mellitus, Type 2 | Details |
| Prusogliptin | DBPR-108 | Approved | National Health Research Institutes, Taiwan Shenlong Co Ltd | 善泽平 | Mainland China | Diabetes Mellitus, Type 2 | Cspc Ouyi Pharmaceutical Co Ltd | 2025-01-08 | Diabetes Mellitus, Type 2; Hepatic Insufficiency; Renal Insufficiency | Details |
| Linagliptin | BI-1356; BI-1356-BS | Approved | Boehringer Ingelheim International Gmbh | 欧唐宁, Ondero, Trajenta, Trayenta, Trazenta, Tradjenta | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2011-05-02 | Albuminuria; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Diabetes Mellitus; Diabetes Mellitus, Type 2; Endocrine System Diseases; Glucose Metabolism Disorders; Hepatic Insufficiency; Hyperglycemia; Hypertension; Inflammation; Metabolic Diseases; Prediabetic State; Renal Insufficiency; Respiratory Tract Diseases; Schizophrenia; Ventricular Dysfunction, Left | Details |
| Rosuvastatin Calcium/Gemigliptin L-tartrate Sesquihydrate | Approved | Lg Chemical Ltd | ZemiStatin | South Korea | Diabetes Mellitus, Type 2; Dyslipidemias | Lg Chemical Ltd | 2017-07-31 | Diabetes Mellitus, Type 2; Dyslipidemias | Details | |
| Alogliptin Benzoate | SYR-322; TAK-322 | Approved | Takeda Pharmaceutical Co Ltd | Nesina, 尼欣那, Vipidia | Japan | Diabetes Mellitus, Type 2 | Takeda Pharmaceutical Co Ltd | 2010-04-06 | Acute Coronary Syndrome; Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Empagliflozin/Linagliptin/Metformin | Approved | Boehringer Ingelheim International Gmbh, Eli Lilly And Company | Trijardy XR | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2020-01-27 | Diabetes Mellitus, Type 2 | Details | |
| Sitagliptin Phosphate/Metformin Hydrochloride | Approved | Merck & Co Inc | Velmetia, Janumet, 捷诺达 | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2007-03-30 | Diabetes Mellitus, Type 2 | Details | |
| Teneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate | Approved | Daiichi Sankyo Co Ltd, Mitsubishi Tanabe Pharma Corp | Canalia | Japan | Diabetes Mellitus, Type 2 | Daiichi Sankyo Co Ltd, Mitsubishi Tanabe Pharma | 2017-07-03 | Diabetes Mellitus, Type 2 | Details | |
| Anagliptin/Metformin Hydrochloride | SK-1501 | Approved | Sanwa Kagaku Kenkyusho Co Ltd, Suzuken | Metoana | Japan | Diabetes Mellitus, Type 2 | Sanwa Kagaku Kenkyusho Co Ltd | 2018-09-21 | Diabetes Mellitus, Type 2 | Details |
| Vildagliptin/Metformin Hydrochloride | LMF-237 | Approved | Novartis Pharma Ag | 宜合瑞, Eucreas, EquMet, Zomarist, Icandra, Galvusmet | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-11-14 | Diabetes Mellitus, Type 2 | Details |
| Sentagliptin Phosphate | CGT-8012 | Approved | Cgenetech(Suzhou China) Co Ltd | 盛捷维 | Mainland China | Diabetes Mellitus, Type 2 | Cgenetech(Suzhou China) Co Ltd | 2024-12-01 | Diabetes Mellitus, Type 2 | Details |
| Alogliptin Benzoate/Metformin Hydrochloride | CT-L01; CT-L-01 | Approved | Takeda Pharmaceutical Co Ltd | Vipdomet, Inisync, Kazano | United States | Diabetes Mellitus, Type 2 | Takeda Pharmaceuticals USA Inc | 2013-01-25 | Diabetes Mellitus, Type 2 | Details |
| Fultagliptin Benzoate | FCN-005; SAL067; SAL-067 | Approved | 信立汀 | Mainland China | Diabetes Mellitus, Type 2 | Shenzhen Salubris Pharmaceuticals Co Ltd | 2024-06-28 | Diabetes Mellitus, Type 2; Renal Insufficiency | Details | |
| Cofrogliptin | HSK7653; HSK-7653 | Approved | Liaoning Haisco Pharmaceutical Co Ltd, Sichuan Haisco Pharmaceutical Co Ltd | 倍长平 | Mainland China | Diabetes Mellitus, Type 2 | Haisco Pharmaceutical Group Co Ltd | 2024-06-18 | Diabetes Mellitus, Type 2; Glucose Intolerance; Renal Insufficiency | Details |
| Anagliptin | SK-0403; CWP-0403 | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Suiny, Beskoa | Japan | Diabetes Mellitus, Type 2 | null | 2012-09-28 | Diabetes Mellitus, Type 2 | Details |
| Dapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride | Approved | Astrazeneca Plc | Qtern | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2016-07-15 | Diabetes Mellitus, Type 2 | Details | |
| Alogliptin Benzoate/Pioglitazone Hydrochloride | SYR-322-4833 BL | Approved | Takeda Pharmaceutical Co Ltd | Nesinaact, Oseni, Liovel, Incresync | Japan | Diabetes Mellitus, Type 2 | Takeda Pharmaceutical Co Ltd | 2011-07-01 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin Phosphate Monohydrate | ONO-5435A; ONO-5435; MK-0431; MK-431; L-000224715 | Approved | Merck Sharp & Dohme Corp | Ristaben, Xelevia, Tesavel, Glactiv, 捷诺维, Januvia, DIABIT-IS X | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2006-10-16 | Atherosclerosis; Carcinoma, Hepatocellular; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Cystic Fibrosis; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastroparesis; Glucose Intolerance; Graft vs Host Disease; Heart Failure; Hepatic Insufficiency; Hepatitis C; HIV Infections; Hyperlipidemias; Inflammation; Insulin Resistance; Kidney Failure, Chronic; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Metabolic Dysfunction-Associated Steatotic Liver Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prediabetic State; Psoriasis; Renal Insufficiency; Renal Insufficiency, Chronic | Details |
| Trelagliptin Succinate | TAK-472; SYR-472; SYR-111472; SYR-111472 succinate | Approved | Takeda Pharmaceutical Co Ltd | Zafatek | Japan | Diabetes Mellitus, Type 2 | Takeda Pharmaceutical Co Ltd | 2015-03-26 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Evogliptin Tartrate/Metformin Hydrochloride | DA-1229_01 | Approved | Dong-A Pharmaceutical Co Ltd | Sugamet XR | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-12-01 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Ertugliflozin | Approved | Pfizer Inc | Steglujan | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2017-12-19 | Diabetes Mellitus, Type 2 | Details | |
| Retagliptin Phosphate/Metformin Hydrochloride | HRX-0701; HRX0701 | Approved | Jiangsu Hengrui Medicine Co Ltd | 瑞霖唐 | Mainland China | Diabetes Mellitus, Type 2 | Shandong Shengdi Pharmaceutical Co Ltd | 2025-05-20 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Metformin Hydrochloride (Zydus Lifesciences) | Approved | Zydus Lifesciences Ltd | Zituvimet, ZITUVIMET | United States | Diabetes Mellitus, Type 2 | Zydus Lifesciences Ltd | 2023-11-03 | Diabetes Mellitus, Type 2 | Details | |
| Omarigliptin | MK-3102 | Approved | Merck & Co Inc | Marizev | Japan | Diabetes Mellitus, Type 2 | Merck Sharp & Dohme Corp | 2015-09-28 | Diabetes Mellitus; Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic | Details |
| Henagliflozin/metformin/retagliptin (Shandong Shengdi) | HR20031; HR-20031 | Approved | Shandong Shengdi Pharmaceutical Co Ltd | 瑞乐唐 | Mainland China | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Shandong Shengdi Pharmaceutical Co Ltd | 2025-10-21 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Teneligliptin/Pioglitazone | Approved | Glenmark Pharmaceuticals Ltd | Zita Plus Pio | India | Diabetes Mellitus, Type 2 | Glenmark Pharmaceuticals Ltd | 2022-04-25 | Diabetes Mellitus, Type 2 | Details | |
| Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate | SID-1903; DW-6012 | Approved | Dong Wha Pharm Co Ltd | Sidapvia | South Korea | Diabetes Mellitus, Type 2 | Dong Wha Pharm Co Ltd | 2023-06-30 | Diabetes Mellitus, Type 2; Myocardial Infarction; ST Elevation Myocardial Infarction | Details |
| Metformin Hydrochloride/Sitagliptin Hydrochloride | Approved | Sandoz Bv | EU | Sandoz Bv | 2019-12-10 | Details | ||||
| Sitagliptin Tartrate | Approved | Heumann Pharma GmbH & Co Generica KG | Sitagliptin Heumann 25 mg Filmtabletten | EU | Heumann Pharma GmbH & Co Generica KG | 2020-12-14 | Diabetes Mellitus, Type 1; Diabetic Nephropathies; Metabolic Dysfunction-Associated Steatotic Liver Disease; Parkinson Disease | Details | ||
| Sitagliptin Hydrochloride | Approved | Laboratorios Alter Sa | Spain | Diabetes Mellitus, Type 2 | Laboratorios Alter Sa | 2019-03-06 | Diabetes Mellitus, Type 2; Polycystic Ovary Syndrome | Details | ||
| Gemigliptin/Dapagliflozin | Approved | Lg Chemical Ltd | Zemidapa | South Korea | Diabetes Mellitus, Type 2 | Lg Chemical Ltd | 2022-06-21 | Diabetes Mellitus, Type 2 | Details | |
| Linagliptin/Metformin Hydrochloride | GC2129A; GC-2129-A; DW6013 | Approved | Boehringer Ingelheim International Gmbh | Jentadueto Xr, Trajenta Duo, Jentadueto, 欧双宁 | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2012-01-30 | Diabetes Mellitus, Type 2 | Details |
| Linagliptin/Empagliflozin | BI 1356/BI 10773; BI 10773/linagliptin; BI 1356/empagliflozin; Empagliflozin/BI 1356; Linagliptin/BI 10773; BI 10773/BI 1356 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Tradiance, Glyxambi, Esgliteo | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2015-01-30 | Cardiovascular Diseases; Diabetes Mellitus, Type 2 | Details |
| Vildagliptin | LAF-237; DSP-7238; LAF-237A; NVP-LAF-237 | Approved | Novartis Pharma Ag | 佳维乐, Equa, Jalra, Galvus, Gliptus, Xiliarx | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-09-25 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dyslipidemias; Insulin Resistance; Prediabetic State; Renal Insufficiency; Schizophrenia | Details |
| Saxagliptin Hydrochloride/Metformin Hydrochloride | Approved | Astrazeneca Plc | 安立格, Kombiglyze Xr, Komboglyze | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2010-11-05 | Diabetes Mellitus, Type 2 | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :